8C5 Stock Overview A biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Coherus BioSciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Coherus BioSciences Historical stock prices Current Share Price US$1.40 52 Week High US$3.34 52 Week Low US$0.61 Beta 0.86 1 Month Change 40.26% 3 Month Change 51.59% 1 Year Change -22.35% 3 Year Change -90.94% 5 Year Change -91.43% Change since IPO -88.05%
Recent News & Updates
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025 Dec 19 Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million. Dec 04
New major risk - Revenue and earnings growth Nov 16
No longer forecast to breakeven Nov 08
Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Market cap size Oct 18 See more updates
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025 Dec 19 Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million. Dec 04
New major risk - Revenue and earnings growth Nov 16
No longer forecast to breakeven Nov 08
Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Market cap size Oct 18
Forecast breakeven date pushed back to 2025 Aug 11
Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.49 loss in 2Q 2023) Aug 09
Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
New major risk - Share price stability Jul 02
Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors Jun 06
Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 24
Forecast breakeven date moved forward to 2024 May 12
First quarter 2024 earnings released: EPS: US$0.91 (vs US$0.95 loss in 1Q 2023) May 10 Coherus BioSciences, Inc. announced that it has received $38.7 million in funding May 10
Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer May 09
Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting Apr 24
Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024 Apr 16
Full year 2023 earnings released: US$2.53 loss per share (vs US$3.76 loss in FY 2022) Mar 14
Forecast breakeven date pushed back to 2026 Mar 14
Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Mar 06
New major risk - Financial position Feb 28
Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 22 Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million. Jan 22
Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium Jan 19
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Dec 27 Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer
Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023 Dec 08
Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress Dec 06
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Nov 29 Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023 Nov 08
Third quarter 2023 earnings released: US$0.41 loss per share (vs US$1.12 loss in 3Q 2022) Nov 07 Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023
Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Oct 28
Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 16
Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody Oct 06
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections Sep 26
Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others. Sep 09
Second quarter 2023 earnings released: US$0.49 loss per share (vs US$0.65 loss in 2Q 2022) Aug 03
Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Aug 03
Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors Jul 23
Coherus Launches Yusimry™, A Biosimilar of Humira® Jul 04 Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million. Jun 18
Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. May 18
Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. May 17
Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023 May 10
First quarter 2023 earnings released: US$0.95 loss per share (vs US$1.24 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$3.76 loss per share (vs US$3.81 loss in FY 2021) Mar 08
Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02 Feb 16
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Dec 26
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$1.12 loss per share (vs US$0.49 loss in 3Q 2021) Nov 10
Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Oct 13
Coherus to Launch Cimerli (Ranibizumab-Eqrn) in the United States on October 3, 2022 Sep 20
Coherus BioSciences, Inc. Announces Executive Changes Sep 10
Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.40 loss in 2Q 2021) Aug 05
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity Aug 03
Coherus BioSciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Jul 07
Coherus BioSciences Appoints Jill O’Donnell-Tormey to Its Board of Directors, Nominating and Corporate Governance Committee of the Board of Directors May 12
First quarter 2022 earnings released: US$1.24 loss per share (vs US$2.38 loss in 1Q 2021) May 07
Coherus Biosciences, Inc. Appoints Charlie Newton to Board of Directors, Member of Audit Committee May 06
Coherus BioSciences, Inc. to Report Q1, 2022 Results on May 05, 2022 May 02
High number of new and inexperienced directors Apr 27
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting Apr 09
Coherus BioSciences, Inc., Annual General Meeting, May 17, 2022 Apr 05
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell Mar 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 18
Coherus BioSciences, Inc. Appoints Paul Reider as Chief Commercial Officer Feb 16
Coherus BioSciences, Inc. to Report Q4, 2021 Results on Feb 17, 2022 Feb 12
Coherus BioSciences, Inc. Announces Management Changes Feb 08
Coherus BioSciences, Inc. Announces U.S. FDA Approval of YUSIMRY Dec 21
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Positive Interim Overall Survival Results of CHOICE-01, A Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Dec 15
Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.39 profit in 3Q 2020) Nov 09
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer Sep 15
Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Sep 02
Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Positive Interim Results from the Pivotal Study Choice-01 Aug 20
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma Aug 13
Independent Director Mary Szela has left the company Aug 12
Second quarter 2021 earnings released: US$0.40 loss per share (vs US$0.83 profit in 2Q 2020) Aug 08 Shareholder Returns 8C5 DE Biotechs DE Market 7D -8.4% -2.9% -2.6% 1Y -22.3% -14.7% 6.9%
See full shareholder returns
Return vs Market: 8C5 underperformed the German Market which returned 7.1% over the past year.
Price Volatility Is 8C5's price volatile compared to industry and market? 8C5 volatility 8C5 Average Weekly Movement 24.8% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 8C5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8C5's weekly volatility has increased from 17% to 25% over the past year.
About the Company Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.
Show more Coherus BioSciences, Inc. Fundamentals Summary How do Coherus BioSciences's earnings and revenue compare to its market cap? 8C5 fundamental statistics Market cap €163.42m Earnings (TTM ) -€431.28k Revenue (TTM ) €291.68m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8C5 income statement (TTM ) Revenue US$304.34m Cost of Revenue US$168.26m Gross Profit US$136.08m Other Expenses US$136.53m Earnings -US$450.00k
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.0039 Gross Margin 44.71% Net Profit Margin -0.15% Debt/Equity Ratio -300.7%
How did 8C5 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 15:13 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Coherus BioSciences, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Balaji Prasad Barclays Balaji Prasad Barclays
Show 14 more analysts 
